B Cell Activating Factor Induces Drug Resistance in Hairy Cell Leukemia Variant
<b>Background:</b> Chemoresistance is an existing challenge faced in the treatment of the hairy cell leukemia variant (HCL-v). Classical hairy cell leukemia (HCL-c) is very sensitive to the standard of care with purine nucleoside analogs (PNAs) cladribine (cDa) and pentostatin. However,...
Saved in:
| Main Authors: | Claire Fritz, Daniel Feinberg, Akshaya Radhakrishnan, Kayla Klatt, E. Ricky Chan, Philip Rock, Richard Burack, Reshmi Parameswaran |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/4/890 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A
by: Kata Ferenczi, et al.
Published: (2025-05-01) -
Simultaneous Chronic Lymphocytic Leukemia and Hairy Cell Leukemia: a Sporadic Event? A Semantic Point of View.
by: luiza akria, et al.
Published: (2014-08-01) -
Hairy cell leukemia: A decade long experience of North Indian Hematology Center
by: Venkatesan Somasundaram, et al.
Published: (2014-01-01) -
The prevalence of BRAF V600E mutation in hairy cell leukemia: A systematic review and meta-analysis study
by: Mehrdad Payandeh, et al.
Published: (2019-01-01) -
A Successful Case of Vemurafenib and Rituximab for Relapsed Hairy Cell Leukemia
by: QIU Yuchong, et al.
Published: (2025-01-01)